Damian Lewis talking to Professor John McGrath
Making a difference to people living with RDEB means new treatments have to be developed and tested in Clinical Trials.
At present there is no cure and no treatment that makes a significant difference to patients with any form of EB. Treatment is limited to chronic wound care and pain control. As skin is inherently fragile and non healing, even advanced treatments developed to date for other chronic wound conditions do not work effectively for EB skin.
The emergence of regenerative medicine means that for the FIRST time it will be possible to create improved treatments and eventually cures for all types of EB.
These new treatments are likely to involve a combination of cell, gene, protein and drug therapies, all of which (individually or together) strive to correct the genetic weakeness in the skin that causes life long blistering.
Current Clinical Trials https://clinicaltrials.gov/ct2/results?term=epidermolysis+bullosa&pg=3
Dr Waseem Qasim, Professor John McGrath, Professor Jakub Tolar